Sundar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 6.10 M
- Company Age 19 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 25.00%
- Profit Growth 11.79%
- Ebitda 13.99%
- Net Worth -7.36%
- Total Assets -4.66%
About Sundar Pharmaceuticals
Sundar Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 April 2005 and has a history of 19 years and ten months. Its registered office is in Chennai 600 018, Tamil Nadu.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 6.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ramu Krishnan and Ramu Sundaravalli serve as directors at the Company.
Company Details
- Location Chennai 600 018, Tamil Nadu
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239TN2005PTC055911
- Company No.
055911
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Apr 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Sundar Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramu Krishnan  | Director | 08-Apr-2005 | Current |
| Ramu Sundaravalli | Director | 08-Apr-2005 | Current |
Financial Performance of Sundar Pharmaceuticals.
Sundar Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 25% increase. The company also saw a substantial improvement in profitability, with a 11.79% increase in profit. The company's net worth dipped by a decrease of 7.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sundar Pharmaceuticals?
In 2017, Sundar Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sundar Dezire Private LimitedRamu Sundaravalli is a mutual person
Babros Chemicals Private LimitedRamu Krishnan and Ramu Sundaravalli are mutual person
- Sundar Chemicals Private Limited
Ramu Krishnan and Ramu Sundaravalli are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sundar Pharmaceuticals?
Unlock and access historical data on people associated with Sundar Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sundar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sundar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
